ClinicalTrials.gg
CompletedNCT04153435COCAUpdated Jul 25, 2022Results posted

Calcium for Out-of-Hospital Cardiac Arrest

A Phase 2 interventional study of Calcium Chloride and Sodium chloride 0.9% in Heart Arrest, Out-Of-Hospital, sponsored by Lars Wiuff Andersen. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-25.

Sponsored by Lars Wiuff Andersen · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
397
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark — 7 open to participants now, 8 under way, 2 of them phase 3. Out-of-Hospital Cardiac Arrest · Denmark.

Enrollment
13th of 26
397 · median 376
Started
2020
with 3 others
Phase 2
4 of 38
1 open now
Registered
18th of 38
by date
Lead sponsor
2 of 38
Lars Wiuff Andersen

Among the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, this one is the 13th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2020, is one of 4 in phase 2, and was the 18th registered.

Out-of-Hospital Cardiac Arrest

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

Browse Out-of-Hospital Cardiac Arrest studies →

Open to participants now

7 of the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, or all of them as a file.
02

Study summary

This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of calcium during adult out-of-hospital cardiac arrest. 430 adult patients with out-of-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled. The primary outcome is sustained return of spontaneous circulation and key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.

03

Conditions studied

  • Heart Arrest, Out-Of-Hospital
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Out-of-hospital cardiac arrest
  • Age ≥ 18 years
  • Received at least one dose of adrenaline

Exclusion criteria

Exclusion Criteria:

  • Traumatic cardiac arrest - including drowning and external asphyxia (e.g., hanging, strangulation, or foreign object airway obstruction)
  • Known or strongly suspected pregnancy
  • Prior enrollment in the trial
  • Received adrenaline during cardiac arrest before arrival of prehospital personnel with the study drug
  • Clinical indication for calcium administration during the cardiac arrest
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
397 participants (actual)

Study arms

  • Experimental
    Calcium

    The intervention will consist of 5 mmol (10 mL ampoule) of calcium chloride (CaCl2) administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.

    Drug: Calcium Chloride

  • Placebo comparator
    Placebo

    The placebo will consist of 10 mL of 9 mg/mL sodium chloride (NaCl, "normal saline") administered intravenously or intraosseously immediately after the first dose of adrenaline and again after the second dose of adrenaline.

    Drug: Sodium chloride 0.9%

Interventions

  • Calcium chloride 5 mmol

    Also known as: CaCl2

  • DrugSodium chloride 0.9%

    Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Sustained Return of Spontaneous Circulation

    Palpable pulses or other signs of circulation without a need for chest compressions lasting at least 20 minutes.

    Time frame: Before or after hospital arrival (up to 2 hours after the cardiac arrest)

Secondary outcomes

  1. Number of Participants With 30-day Survival

    Time frame: 30 days after the cardiac arrest

  2. Number of Participants With 30-day Favorable Neurological Outcome

    Neurological outcome will be assessed with the modified Rankin Scale (mRS) which is a scale from 0 to 6 assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes. The scale will will be dichotomized as favorable (mRS 0-3) vs. unfavorable (mRS 4-6).

    Time frame: 30 days after the cardiac arrest

07

Results

Posted Feb 25, 2022

Participant flow

Participant flow — Overall Study
MilestoneCalciumPlacebo
Started197200
Completed197200
Not completed00

Outcome measures

PrimaryNumber of Participants With Sustained Return of Spontaneous Circulation

Palpable pulses or other signs of circulation without a need for chest compressions lasting at least 20 minutes.

Time frame:
Before or after hospital arrival (up to 2 hours after the cardiac arrest)
Reported as:
Count of participants · Participants
Number of Participants With Sustained Return of Spontaneous Circulation
ParticipantsCalciumPlacebo
Number of Participants With Sustained Return of Spontaneous Circulation3753
SecondaryNumber of Participants With 30-day Survival
Time frame:
30 days after the cardiac arrest
Reported as:
Count of participants · Participants
Number of Participants With 30-day Survival
ParticipantsCalciumPlacebo
Number of Participants With 30-day Survival1018
SecondaryNumber of Participants With 30-day Favorable Neurological Outcome

Neurological outcome will be assessed with the modified Rankin Scale (mRS) which is a scale from 0 to 6 assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes. The scale will will be dichotomized as favorable (mRS 0-3) vs. unfavorable (mRS 4-6).

Time frame:
30 days after the cardiac arrest
Reported as:
Count of participants · Participants
Number of Participants With 30-day Favorable Neurological Outcome
ParticipantsCalciumPlacebo
Number of Participants With 30-day Favorable Neurological Outcome715

Adverse events

Collected over 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Calcium183/193 (94.8%)——
Placebo180/198 (90.9%)——

Baseline characteristics

All patients received the trial drug and meeting all inclusion criteria and none of the exclusion criteria.

Age, Continuous
Age, Continuous(years)CalciumPlaceboTotal
Mean67 ± 1469 ± 1468 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)CalciumPlaceboTotal
Female6252114
Male131146277
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)CalciumPlaceboTotal
Count of participants——0
08

Study locations

1 site
  • Prehospital Emergency Medical Services
    Aarhus N, Central Denmark Region 8200, Denmark
09

References and documents

Publications

  • Vallentin MF, Granfeldt A, Meilandt C, Povlsen AL, Sindberg B, Holmberg MJ, Iversen BN, Maerkedahl R, Mortensen LR, Nyboe R, Vandborg MP, Tarpgaard M, Runge C, Christiansen CF, Dissing TH, Terkelsen CJ, Christensen S, Kirkegaard H, Andersen LW. Effect of calcium vs. placebo on long-term outcomes in patients with out-of-hospital cardiac arrest. Resuscitation. 2022 Oct;179:21-24. doi: 10.1016/j.resuscitation.2022.07.034. Epub 2022 Jul 30. PubMed 35917866 ↗
  • Vallentin MF, Granfeldt A, Meilandt C, Povlsen AL, Sindberg B, Holmberg MJ, Iversen BN, Maerkedahl R, Mortensen LR, Nyboe R, Vandborg MP, Tarpgaard M, Runge C, Christiansen CF, Dissing TH, Terkelsen CJ, Christensen S, Kirkegaard H, Andersen LW. Effect of Intravenous or Intraosseous Calcium vs Saline on Return of Spontaneous Circulation in Adults With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2021 Dec 14;326(22):2268-2276. doi: 10.1001/jama.2021.20929. PubMed 34847226 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Six months after the publication of the last results, all deidentified individual patient data will be made available for data sharing. Procedures, including re-coding of key variables, will be put in place to allow for complete deidentification of the data. Data will be completely anonymized according to Danish law.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Six months after the publication of the last results

Access criteria: Data will be available for any research purpose to all interested parties who have approval from an independent review committee and who have a methodological sound proposal as determined by the steering committee of the current trial. Only the methodological qualities and not the purpose or objective of the proposal will be considered.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Apr 2021, 14 months.

Results were first posted in Feb 2022, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2019
First posted
Nov 6, 2019
StartActual
Jan 20, 2020
Primary completionActual
Apr 15, 2021
CompletionActual
Apr 15, 2022
Results first posted
Feb 25, 2022
Last update
Jul 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04153435
Lead sponsor
Lars Wiuff Andersen
Collaborators
Central Denmark Region, University of Aarhus
Responsible party
Lars Wiuff Andersen (Associate Professor, Aarhus University Hospital) — Sponsor-investigator
First posted
Nov 6, 2019
Start date
Jan 20, 2020
Primary completion
Apr 15, 2021
Completion
Apr 15, 2022
Results posted
Feb 25, 2022
Last update
Jul 25, 2022

Study contacts

Lars W Andersen
principal investigator · Aarhus University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calcium Chloride

Start the discussion